Table 1. Demographic data on seven male IPMT patients diagnosed between 1994 and 1998.
| Case | Age (yr) | Symptoms | US FNAC | CT | MR | ERCP/brush cytology |
|---|---|---|---|---|---|---|
| 1 | 46 | pain, loss of weight | cyst – | cyst, duct ectasia | – | communicating cysts/dysplasia, mucin, duct ectasia |
| 2 | 68 | loss of weight, steatorrhoea | multi-cystic | – | – | IPMT/CIS, duct ectasia |
| 3 | 54 | loss of weight, steatorrhoea | cystic mass in caput, normal cells | – | – | duct ectasia, normal cells, mucin, communicating cysts |
| 4 | 73 | loss of weight, pain, steatorrhoea | mass in head of pancreas, normal cells | mass in head of pancreas | – | duct ectasia, severe dysplasia, mucin |
| 5 | 65 | pain, diabetes, loss of weight, alcohol | mass in caput, dilated duct, normal cells | dilated duct | duct ectasia with tumour in duct | duct ectasia, dysplasia, mucin, tumour |
| 6 | 39 | pain, loss of weight, pancreatitis | dilated duct | – | – | duct ectasia, normal cells, suspicion for either tumour or mucin (filling defect). |
| 7 | 75 | loss of weight | liver metastases carcinoma | – | – | duct ectasia, dysplasia, mucin |
US = ultrasound; FNAC = fine-needle aspiration cytology; CT = computed tomography; MR = magnetic resonance imaging; ERCP = endoscopic retrograde cholangiopancreatography; IPMT = intraductal papillary mucinous tumour; CIS = carcinoma in situ; caput = head of pancreas.